Quality and IP issues driving sponsors away from Indian CMOs, experts say

By Dan Stanton

- Last updated on GMT

Experts: Quality and IP issues driving sponsors away from Indian CMOs

Related tags: Contract manufacturing, India, Us

Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing according to experts, but Kemwell says there are still opportunities for Indian CMOs.

Two Decades ago “with low capital, material and labour costs, and high quality Western standards it seemed that India was destined to capture a considerable volume of contract manufacturing from European and North American contractors,”​ Jim Browne, director of JTB Consulting and former director external supply at GlaxoSmithKline told Outsourcing-Pharma.com.

But while “there were many initial successes,”​ he continued, “the full potential of this transition has never been fully realisedand some production has even returned to European and North American contractors.”

Escalating wages and raw material prices, along with shipping and logistic costs have closed the gap on the perceived cost benefits, he said, whilst problems with intellectual property (IP) stemming from the rapid transition of senior staff between fast growing local companies are also making the country less attractive to Western drugmakers.

The third factor pushing manufacturing back West are quality concerns, Browne added.  Though a number of high quality EU and US FDA approved export only pharmaceutical plants were constructed in the 2000s, “quality issues began to subsequently appear in operating procedures, standards and maintenance.”

Sponsors turning their backs?

These issues have materialised in a number of recent high profile regulatory findings - notably US import bans from products made at Wockhardt​ and Ranbaxy​ facilities – adding to a push away from India.

Quality concerns were echoed by Brad Carlson, VP of Marketing and Sales at CMO Aenova, who told us he had experienced colleagues and customers turning their back on India due to the increasing regulatory concern.

You start to see some of those customers moving back and saying the supply chain coming from India and China is really not the reliable supply chain they are looking for,”​ he said at the recent Interphex meeting in New York.

Though sponsors were reluctant to talk openly on this subject, Richard Fazackerley – Associate Director at Eisai – told delegates at the Global Pharmaceutical Contract Manufacturing (GPCM) Conference last year​ his firm was bringing products back due in part to quality, as “the consequences are failure of the product and brand.”

However, a former employee of a multinational drug firm, who asked to remain anonymous, told us though the company’s “regulatory groups were uncomfortable about the GxP status of the facilities,”​ and put off by the “limited precedence of US or European drug agency inspections,”​ in their experience contracting firms to make materials for drug candidates for preclinical studies (non-GMP) they “always found the quality high, communication good and the price low.”

Indian CMO opportunities

Outsourcing-Pharma.com also spoke with Indian contract manufacturer Kemwell Biopharma, which said though quality concerns are a hot topic in conversations with customers, the company has the opportunity to “stand apart from the crowd,”​ reporting a 25 percent growth in orders last year

Regarding recent Warning Letters and Consent Decrees in India, Managing Director Anurag Bagaria told us “the number of such incidents is alarming and obviously the Indian pharma industry has to address this in a timely manner.”

However, “these issues are not prevalent in India alone as the FDA and other regulators are tightening and raising the GMP bar worldwide,” ​he added. “I hope our customers will differentiate between the various service providers and make case-to-case decisions as they do in other parts of the world.”

As for the IP issue cited by Browne, Bagaria said: “At Kemwell specifically, we are taking many proactive steps to maintain IP protection such as IT controls, background checks of employees, training to sensitize employees on the importance of IP, CDAs with employees.”

Furthermore, Bagaria told us whilst there are problems with Indian IP regulations and the industry must work with the Government to improve this, such rules do not affect contract manufacturing for Western firms.

“The IP that a sponsor shares with their CDMO partner in India continues to be protected by Indian law and cannot be licensed to the competitors of the sponsors by the government or any other body.”

Related news

Show more

Related products

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more